In contrast, the mitogen-activated protein kinase pathway remains responsive to insulins vasoconstrictive actions via endothelin-1 (ET-1), a potent vasoconstrictor
Tirzepatide commonly causes nausea, vomiting, diarrhea, and decreased appetite, particularly during initiation and dose escalation
But clinical trial averages don't predict your personal outcome, and results from FDA-approved formulations in controlled trials don't certify identical performance from a compounded formulation
The appetite-suppressing effects occur through complex interactions with the central nervous system, which has led researchers to hypothesise that these medications might influence other reward-driven behaviours, including alcohol consumption
No unexpected serious safety signals have been reported so far, but the full safety dataset will take TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and eventually TRIUMPH-CVOT to characterize